Multiple myeloma (MM) is a non-curable tumor developing in the bone marrow (BM). The BM microenvironment rich in hematopoietic precursors is suspected to have a role in MM development. Here we show that a proliferation-inducing ligand (APRIL) mediated in vivo MM promotion. In MM-infiltrated BM, APRIL originated from differentiating myeloid cells with an expression peak in precursor cells. Notably, APRIL expression stayed stable in BM despite MM infiltration. The pool of APRILproducing cells changed upon MM infiltration. Although CD16 + mature myeloid cells constituted about half of the APRIL-producing cells in healthy BM, CD16 − Elastase + myeloid precursor cells were predominant in MM-infiltrated BM. Myeloid precursor cells secreted all the APRIL they produced, and binding of secreted APRIL to MM cells, strictly dependent of heparan sulfate carried by CD138, resulted in an in situ internalization by tumor cells. This indicated APRIL consumption by MM in BM. Taken together, our data show that myelopoiesis dysregulation characterized by an increased proportion of precursor cells occurs in MM patients. Such dysregulation correlates with a stable expression of the MM-promoting factor APRIL in infiltrated BM.
INTRODUCTION
Multiple myeloma (MM) is a hematological tumor originating from plasma cells (PCs). Relapses are still uncontrolled despite the dramatic improvement in treatment responses obtained over the last decade. 1 The microenvironment is now viewed as an important player in the development of many tumors, 2 including MM. 3 APRIL, a member of the tumor necrosis factor family, is considered as a MM-promoting factor from the microenvironment. APRIL has two signaling receptors, the transmembrane activator, calcium modulator and cyclophilin ligand interactor (TACI) and the B-cell maturation antigen (BCMA). APRIL differs from most tumor necrosis factor family members by requiring heparan sulfate proteoglycan as coreceptor to insure its oligomerization and active receptor signaling. [4] [5] [6] Functionally, the main cellular targets of APRIL are PCs. 7 PCs express BCMA and TACI, ubiquitously and variably, respectively, as well as a unique heparan sulfate proteoglycan, CD138 also known as syndecan-1. APRIL mediates PC differentiation by inducing isotype switching, 8 participates in the proliferation of plasmablasts in secondary lymphoid organs 9 and sustains long-term PC survival in BM. 10, 11 In BM, APRIL expression is mostly restricted to cells from the myeloid lineage, including eosinophils, monocytes/macrophages and osteoclasts. [12] [13] [14] In fact, APRIL expression and secretion starts early in the myeloid lineage at the precursor stage. 15 Megakaryocytes also produce APRIL. 16 Malignant transformation does not change APRIL receptor expression on MM cells, and as a consequence, APRIL also acts on MM cells. In MM, APRIL increases cell cycle progression and survival. [17] [18] [19] In a mouse preclinical model, a soluble form of TACI reduces tumor development in fetal bones implanted into immunodeficient mice. 14 APRIL also confers some resistance to chemotherapeutic drugs. 17 Soluble TACI also antagonizes the related B-cell activation factor from the tumor necrosis factor superfamily (BAFF). 20 The fact that BAFF has a role in the same SCID-Hu model 21 renders the specific contribution of APRIL not yet ascertained. Here we demonstrate for the first time an in vivo role of APRIL in MM development, and characterize the cellular source of APRIL in MM-infiltrated BM.
MATERIALS AND METHODS

Human and animal experimentation
All mouse experiments were performed in the animal facility of the Geneva Medicine Faculty. The veterinary office of the Geneva canton and the central research ethical committee of the Geneva Hospital University approved animal and human experimentations, respectively. Trephine biopsies and bone marrow aspirates were used from MM and healthy patients as described. 15 For the xenogeneic MM model, C57/Bl6 APRIL −/− mice, kindly provided by Dr R Askhenazy (Genentech, San Francisco, CA, USA), were backcrossed six times on a NOD/SCID (Charles River, Wilmington, MA, USA) background. L363 and U266 MM, and HEK epithelial cell lines were from the American tissue culture collection. A total of 5 × 10 5 tumor cells were injected subcutaneously in 0.1 ml phosphate buffered saline. Tumor engraftment was recorded by skin palpation and confirmed by histology. Immunohistochemistry BM biopsies were stained with Stalk-1, recognizing APRIL-producing cells, and Aprily-2, recognizing secreted APRIL, as described. 22 The anti-CD138 was from Dako (Glostrup, Denmark) and used according to the manufacturer's instructions. The anti-CD16 mAb 2H7 (Leica Microsystems, Wetzlar, Germany) was used after heat-induced epitope retrieval in Tris-EDTA pH 9.0 buffer at 4 μg/ml, respectively. The IgM anti-HS 10e4 (Seikagaku Corporation, Tokyo, Japan) was used at 5 μg/ml without heat-induced epitope retrieval treatment. Detection was performed with the peroxidase-based envision kit (Dako). Two-color peroxidase/alkaline phosphatase-based immunohistochemistry staining was performed with the envision rabbit/mouse doublestain system from Dako according to the manufacturer's instructions. Images were treated as previously described. 23 CD16 + cells and APRIL-producing cells were quantified from two distant zones corresponding to a total surface of 1 mm 2 from serial sections.
Flow cytometry (FCM)
L363 and U266 MM cells were stained with the anti-human BCMA and TACI antibodies as previously described. 22 Flag-tagged recombinant multimeric human APRIL (a88) was from Adipogen SA (Epalinges, Switzerland). APRIL binding was monitored with a biotinylated form of an anti-tag antibody (Clone M2, Sigma, St Louis, MO, USA) followed by fluorochrome-conjugated streptavidin (BD Biosciences, San Jose, CA, USA). Flag-tagged recombinant multimeric Tweak was used as an irrelevant control. A fluorescein isothiocyanate (FITC)-conjugated form of the anti-HS 10e4 was used (Seikagaku Corporation). Other fluorochoromeconjugated antibodies were from BD Biosciences. Sodium chlorate (Sigma), heparitinase (Seikagaku Corporation) and chondroitinase (Seikagaku Corporation) cellular treatments were performed as previously described. 4, 6, 24 Human fresh BM cells were obtained from aspirates and processed as previously described. 15 Fluorescence-activated cell sorting was performed on FACSARIA (BD Biosciences). Ex vivo intracellular staining was performed on cells fixed with 1% formaldehyde and permeabilized with 1% saponin.
Enzyme-linked immunosorbent assay
Precoated plates of the human APRIL-specific sandwich enzyme-linked immunosorbent assay was used following the manufacturer's instructions (e-biosciences, San Diego, CA, USA).
Quantitative real time PCR
Total RNA was extracted from fluorescence-activated cell-sorted cells using Trizol (Life Technologies, Paisley, UK), and cDNA was generated using random primers and the SuperScript II reverse transcriptase (Life Technologies). MRNA expression was measured by real time PCR using the iCycler iQ Real-Time PCR detection system (Bio-Rad, Hercules, CA, USA) and a SYBRgreen-based kit (iQ Supermix, Bio-Rad). Samples were assayed twice in triplicates. Results are shown as relative expression. Primers have already been described. 15 
Statistical analysis
Two-tailed paired t-tests were performed. A log-rank test was performed for the xenograft experimentation. P-values superior to 0.05 are considered as nonsignificant. ( Figure 1a ). They are representative of the two MM subsets, TACI low/neg and TACI high previously reported. 25 Both cell lines expressed the CD138 APRIL-coreceptor and bound efficiently recombinant soluble APRIL. The lack of APRIL equally impaired the subcutaneous development of U266 and L363 in SCID mice, whereas the growth of the unrelated HEK epithelial cell line was not affected. This xenogeneic model revealed that APRIL by itself is crucial for in vivo MM development.
RESULTS
In vivo role of APRIL for MM development
Stable expression of APRIL from myeloid origin despite MM infiltration of BM By studying APRIL expression in BM from MM patients, we observed abundant APRIL-producing cells in the BM tissue surrounding tumor cells ( Figure 2a ). MM tumor cells did not produce APRIL by themselves. FCM analysis of BM aspirates from MM patients confirmed the paracrine nature of APRIL, and allowed the characterization of its cellular source in the BM Secrtetd APRIL (ng/ml) microenvironment. Myeloid but not lymphoid hematopoietic cells produced APRIL (Figure 2b ). In this experiment, we observed a higher intracellular APRIL protein expression in CD16 − myeloid precursor cells compared with CD16 + mature cells (19 MFI ± 5.1 vs 11 MFI ± 2.5, Po 0.01). MRNA analysis confirmed the peak of APRIL production in myeloid precursor cells (Figure 2c ). We also analyzed secreted APRIL in BM aspirates. Notably, we observed no significant change between healthy and MM-infiltrated BMs, indicating a quite stable expression of APRIL despite BM infiltration of up to 60% (Figure 2d ). Taken together, our data show that myelopoiesis is an important source of APRIL in MMinfiltrated BM with a production peak in myeloid precursor cells, very similar to the one previously reported in healthy BM. 15 Our data also indicate that some changes have to occur in the BM microenvironment to explain APRIL stability of expression in MM-infiltrated BM.
Abnormal myelopoiesis in BM from MM patients
To decipher the cellular pathway explaining APRIL stability despite infiltration in MM, we first quantified the total number of APRILproducing cells in infiltrated BM. We could not use BM aspirates as they are frequently and variably contaminated by blood. 26 We favored an in situ approach, and analysis of the tissue surrounding tumor cells showed no increase in the total number of APRILproducing cells in healthy compared with MM-infiltrated BM with 532 ± 31, n = 34 and 618 ± 44, n = 13 per 1 mm 2 of sections, respectively (Figure 3a, upper panel) . We next further characterized in situ APRIL-producing cells. Osteoclasts produce APRIL, at least when differentiated in vitro, 13, 14 and APRIL stability of expression could potentially be explained by the increased osteoclast number observed in MM-infiltrated BM. 27 However, we did not detect APRIL expression in osteoclasts present in MM-infiltrated BM (Supplementary Figure 1A) . Megakaryocytes, producing APRIL in murine healthy BM, were also negative in MM-infiltrated BM (Supplementary Figure 1B) . We next analyzed the myeloid lineage with CD16, a marker of mature cells. 28 CD16 + myeloid cells were present in the pool of APRIL-producing cells from healthy BM (Figure 3a, bottom panel) . In contrast, some MM patients showed a complete loss of CD16 + myeloid cells in BM. We calculated 47.1% ± 2.9 and 17.5% ± 2.6 of CD16 + cells constituting the total pool of APRIL-producing cells in healthy and MM-infiltrated BM, respectively, with this serial section analysis. In total, 8/34 MM patients had no more mature myeloid cells in the BM biopsy analyzed, and 18/34 showed a significant downregulation (that is, less than normal mean value − 3 × s.d.). Elastase is a specific enzyme present in the primary granules formed during myeloid differentiation. 29 In the eight MM patients without CD16 + cells in BM, the APRIL-producing cells were positively stained for elastase demonstrating their myeloid origin (Figure 3b ). Hence, the myeloid compartment in MM-infiltrated BM was shifted towards an increased proportion of myeloid precursor cells. Patients with a known percentage of MM infiltration in BM further indicated that the shift was an early event since occurring with as low as 5% of MM-cell infiltration (Figure 3c ). Such increased proportion of high APRIL-producing myeloid precursor cells is a likely explanation for the stable level of APRIL expression in BM from MM patients reported above.
In situ internalization of paracrine APRIL by MM cells Figure 1a shows that recombinant soluble APRIL bound to MM cell lines and Figure 2d further shows that there was a high concentration of soluble APRIL in the fluid of MM-infiltrated BM. We next assessed the in situ binding of soluble APRIL onto MM cells. Previous investigation showed that soluble APRIL binding to MM cells was dependent on heparan sulfate (HS) chains from CD138. 18 We further show that total abrogation of sulfation by short-term treatment with sodium chlorate in MM cell lines inhibited soluble APRIL binding (Figure 4a ). In addition to HS, CD138 also bears another sulfated glycan structure in the form of chondroitin sulfate chains. 30, 31 Inhibition by heparitinase but not chondroitinase confirmed that APRIL binding was dependent on HS, and showed that chondroitin sulfate structures were not involved. The complete inhibition seen with sodium chlorate and heparitinase further shows that HS on CD138 mediated the primary binding of soluble APRIL on MM cells without involvement of the signaling receptors TACI and BCMA. 10e4 is a monoclonal antibody recognizing specific pattern present on some but not all HS chains. 32 10e4 recognized HS chains on CD138 expressed by MM cell lines (Figure 4b, left panel) . Chlorate sodium and heparitinase treatments have already been reported to inhibit 10e4 reactivity, 33 and we observed similar inhibition (data not shown). CD138 and 10e4 staining gave narrow and wide (over two log) fluorescence peaks, respectively. This indicates that CD138 expression level was quite homogeneous among MM cells, whereas HS expression level on CD138 varied. Notably, we also observed a quite wide fluorescence peak for soluble APRIL binding (Figure 4b, middle panel) . Finally, the cell population binding the most 10e4 also bound the most soluble APRIL, showing a correlation between 10e4 and soluble APRIL reactivity (Figure 4b, right panel) . We next used 10e4 reactivity to analyze the ability of primary MM cells to bind APRIL. In situ staining on serial sections shows that most if not all CD138 + MM cells were 10e4 reactive (Figure 5a ). We previously reported that the hematopoietic microenvironment was 10e4 negative in healthy BM. 15 FCM analysis of BM aspirates confirmed that 10e4 reactivity was confined to CD138 + MM cells and absent from the hematopoietic environment (Figure 5b ). Aprily-2 is an anti-APRIL recognizing in situ the secreted portion of APRIL in human tissues. 22 The absence of Aprily-2 staining in myeloid cells in MM-infiltrated BM showed that myeloid cells secreted all the APRIL they produced (Figure 5c, upper panel) . The BM microenvironment did not bind secreted APRIL, confirming its lack of 10e4 reactivity. By contrast, we detected secreted APRIL on some MM tumor cells (Figure 5c, lower panel) . Notably, secreted APRIL was clearly present in the cytoplasm of MM cells, confirming a previous analysis performed with the same Aprily-2 mAb, 19 and implying an internalization of secreted APRIL by tumor cells. Taken together, our data show that MM cells infiltrating BM express HS chains on CD138 able to bind soluble APRIL. MM cells internalize paracrine APRIL, indicating APRIL consumption by MM tumor cells.
DISCUSSION
The in vivo role of APRIL in MM development has never been directly investigated due to the lack of a specific APRIL antagonist.
Here APRIL-deficient SCID mice showed a significant role of APRIL on its own with human MM cell lines grafted in a heterotopic subcutaneous site. A new orthotopic mouse MM model, MOPC-315.BM, was recently generated in Balb/c mice. 34 Unfortunately, MOPC-315.BM did not grow in allogeneic SCID mice (data not shown), avoiding assessment of BM development. However, the internalization of paracrine APRIL observed in situ by MM tumor cells indicates that APRIL is consumed by MM cells, and may therefore fulfill a similar MM-promoting activity in BM. In our setting, the TACI low/neg MM cell line U266, suggested to be less dependent on BM microenvironment factors, 25 was as susceptible to APRIL depletion as the TACI high MM cell line L363. Two independent groups have previously studied soluble APRIL in sera from MM patients. The first group reported a strong upregulation of circulating soluble APRIL in MM patients. 18 The second group reported much less soluble APRIL in MM patients sera with a level in newly diagnosed patients (2.56 ng/ml ± 0.44), and more advanced treated patients (3.01 ng/ml ± 0.27) in the range of healthy individuals (1.59 ng/ml ± 0.41). 35 Our study of APRIL expression performed directly in BM also reveals a quite stable expression despite BM infiltration. The cellular source of APRIL has also been previously investigated by ex vivo/in vitro experimentation. Although some MM cells may produce APRIL, 17 production by the BM microenvironment is much higher. 25 Our study demonstrates that the in situ source of APRIL is indeed paracrine and highly abundant as produced by hematopoietic cells committed in the myeloid lineage. Notably, we are showing that MM development induces myelopoiesis dysregulation characterized by an increase proportion of precursor cells. As APRIL production peaks in myeloid precursor cells, such myelopoiesis dysregulation is likely to result in an increased production of APRIL, explaining the overall stability of APRIL expression in BM from MM patients despite infiltration. This reinforces the therapeutic value of APRIL in MM and its targeting as previously tested with the APRIL/BAFF inhibitor, Atacicept in refractory/ relapsed MM patients. 36 The myelopoiesis dysregulation we observed here is associated with disappearance of the mature compartment in the myeloid lineage. There are several reports in the literature consistent with this observation. First, a large cohort study (n = 1545) revealed a low count of mature neutrophils in blood from up to 51% of MM patients at diagnosis. 37 Second, soluble CD16 shed from the surface of mature neutrophils is downregulated in the blood of MM patients compared with healthy donors. 38, 39 Finally, myelodysplastic syndrome (MDS), a neoplastic disorder affecting myeloid cell maturation, is recognized as being associated to MM. 40 Although first believed to be a secondary pathology arising subsequently to MM treatments, two independent groups reported the presence of MDS-associated cytogenetic alterations in a small proportion (1-2%) of asymptomatic untreated monoclonal gammopathy of undetermined significance. 41, 42 Besides cytogenetic analysis, FCM has been tested to monitor phenotypic alterations associated to MDS. 43 Recently, MDS-related phenotypic alterations detected by FCM, including CD16 downregulation, have been confirmed in monoclonal gammopathy of undetermined significance and extended to a significant fraction of symptomatic MM at diagnosis. 44, 45 In conclusion, MM tumor cells modulate the BM microenvironment by increasing the ratio of immature cells in the myeloid compartment. This sustains an environment rich in promoting factors such as APRIL. Such process may contribute to MDS induction.
